James A. Rogers, Ph.D.

Vice President of Statistics, Quantitative Sciences

Jim Rogers is the Vice President of Statistics in the Quantitative Sciences Business Unit at Metrum Research Group. After receiving his doctorate in statistics from The Ohio State University in 2001, Jim worked for two years on genomic and metabonomic analyses for biotechnology companies, followed by five years at Pfizer Global Research and Development where he worked initially and as a nonclinical statistician and later as a clinical biostatistician. In 2008, Jim joined Metrum Research Group in order to work in closer collaboration with quantitative biologists and pharmacometricians. Over the course of his 15 years at MetrumRG, Jim has worked on decision informatics across a wide range of therapeutic areas and therapeutic modalities. Recurring areas of focus have included problems related to dose selection and dose optimization, as well as platform development based on disease progression models and clinical trial simulation. From a methodological perspective, Jim’s focus in recent years has centered on the role of causal inference concepts in evidence integration. Jim believes that scientists trained in statistics can revolutionize the discipline of pharmacometrics and that scientists trained in pharmacometrics can revolutionize the discipline of statistics.

Recent publications by this scientist

Covariate modeling in pharmacometrics: General points for consideration

April 15, 2024

Covariate analysis is typically performed, and results are reported, based on the purpose of the analysis and the anticipated audience. Failure to use a standard for reporting parameters has made it difficult to find common features of models and use covariate analysis in a consistent way in order to discover new knowledge. This article aims to provide a useful basis for analysts to choose the most appropriate approach for their specific sets of circumstances.

Read Article

MIDD for dose confirmation in special populations: full covariate modeling meets intersection-union testing

March 18, 2024

Presented at the International Symposium on Biopharmaceutical Statistics, March 2024. From basic dose adjustments to more ambitious programs for personalized medicine, pharmacometrics has a long tradition of informing tailored treatment strategies. Many of the modeling strategies are well-precedented, but formal decision frameworks are needed to address the question: how much data is enough to support a decision?

Download PDF

Confounded exposure metrics

November 28, 2023

Exposure-response (E-R) modeling frequently relies on the use of exposure metrics that summarize drug concentrations over time. This research presents simulations to demonstrate that certain commonly used exposure metrics, including average concentration up to an event time, are likely to lead to causal confounding under the very conditions that motivate their use.

Read Article